Richard Aranda
Chief Tech/Sci/R&D Officer bij GOSSAMER BIO, INC.
Vermogen: 234 583 $ op 31-03-2024
Profiel
Richard Aranda is currently the Chief Medical Officer at Gossamer Bio, Inc. He previously worked as the Vice President-Clinical Development at Receptos LLC from 2015 to 2018, the Vice President-Medical Science & Inflammation at Novo-Nordisk Biochem, Inc. from 2011 to 2015, and as a Principal at Bristol Myers Squibb Co. from 2001 to 2011.
Dr. Aranda obtained his undergraduate degree from the University of California, Santa Cruz and holds doctorate degrees from Stanford University School of Medicine and Stanford School of Medicine.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
GOSSAMER BIO, INC.
0.09% | 18-03-2024 | 198 799 ( 0.09% ) | 234 583 $ | 31-03-2024 |
Actieve functies van Richard Aranda
Bedrijven | Functie | Begin |
---|---|---|
GOSSAMER BIO, INC. | Chief Tech/Sci/R&D Officer | 01-06-2021 |
Eerdere bekende functies van Richard Aranda
Bedrijven | Functie | Einde |
---|---|---|
RECEPTOS INC | Corporate Officer/Principal | 01-01-2018 |
Novo-Nordisk Biochem, Inc. | Corporate Officer/Principal | 01-01-2015 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-05-2011 |
Opleiding van Richard Aranda
University of California, Santa Cruz | Undergraduate Degree |
Stanford School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
GOSSAMER BIO, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Receptos LLC
Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Novo-Nordisk Biochem, Inc. |